中国临床药学杂志

参考文献

[1]中华医学会儿科学分会肾脏学组.儿童激素敏感、复发/依赖肾病综合征诊治循证指南(2016)[J].中华儿科杂志, 2017,55(10):729.

[2] KAKU Y, OHTSUKA Y, KOMATSU Y, et al. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013:general therapy[J]. Clin Exp Nephrol, 2015, 19(1):34.

[3]宫雪,王文红.儿童慢性肾脏病生长障碍发病机制的研究进展[J].中国处方药, 2022, 20(7):168.

[4]李雪,吴瑾.儿童生长发育障碍的识别与对策[J].中国临床医生杂志, 2021, 49(2):138.

[5] LOKE K Y, YAP H K, ZHOU X, et al. Efficacy and safety of one year of growth hormone therapy in steroid-dependent nephrotic syndrome[J]. J Pediatr, 1997, 130(5):793.

[6] RIVKEES S A, DANON M, HERRIN J. Prednisone dose limitation of growth hormone treatment of steroid-induced growth failure[J].J Pediatr, 1994, 125(2):322.

[7]易玲,温丽芳,曾海江,等.糖皮质激素对肾病综合征患儿骨代谢影响[J].抗感染学, 2019, 16(1):110.

[8]米秀芳,尹雨桐,顾健.钙和维生素D预防肾病综合征儿童糖皮质激素所致骨量丢失有效性Meta分析[J].临床药物治疗杂志,2019, 17(2):50.

[9]中华医学会儿科学分会.儿科肾脏系统疾病诊疗规范[M].北京:人民卫生出版社, 2016.

[10] BUCKLEY L, GUYATT G, FINK H A, et al. 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis[J]. Arthritis Rheumatol,2017, 69(8):1521.

[11]中华医学会骨质疏松和骨矿盐疾病分会.维生素D及其类似物临床应用共识[J].中华骨质疏松和骨矿盐疾病杂志, 2018, 11(1):1.

[12]卜远波.重组人生长激素液体制剂稳定性的研究[D].长春:吉林大学, 2005:58-63.

[13] SWORDS F M, CARROLL P V, KISALU J, et al. The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement[J]. Clin Endocrinol, 2003, 59(5):613.

[14] AGHA A, MONSON J P. Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axis[J]. Clin Endocrinol, 2007,66(4):459.